$AMGN has released its Q4 2024 earnings, featuring an EPS of $5.31, surpassing expectations by $0.23, and revenues of $9.09B, up 10.86% YoY. The company recorded robust product sales growth of 19% for the full year and sustained momentum across key medications like Repatha and EVENITY, with significant unmet patient needs driving future potential.